Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
Completed · Phase 1
Conditions studied: Primary Ciliary Dyskinesia
In brief
This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
Key facts
- Study ID
- NCT05737485
- Run by
- ReCode Therapeutics
- People needed
- 9
- Starts
- 2023-02-18
- Expected to finish
- 2025-01-13
- Last updated by the study team
- 2025-04-29
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- PPD - Las Vegas Research Unit — Las Vegas, Nevada, United States
- Macquarie University — Sydney, New South Wales, Australia
- New Zealand Clinical Research — Auckland, New Zealand
- Royal Brompton Hospital — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.